VIA Pharmaceuticals, Inc. (VIAP)

[TITAN]

Nice read Alex..Criteria
Inclusion Criteria

Female patients must be of non-childbearing potential
Recent acute coronary syndrome [(ACS) ST elevation myocardial infarction (STEMI), non-STEMI or unstable angina) event documented by ECG, cardiac enzymes or angiogram] 1 - 3 months prior to randomization
Carotid or ascending aorta artery plaque inflammation Target-to-Background Ratio (TBR) ≥ 1.6
Coronary artery inflammation defined as increased FDG-PET update in the left main artery (up to the bifurcation), the proximal right coronary artery or at the site of stent implantation.
Exclusion Criteria

Renal insufficiency defined as creatinine >1.5 x upper limit of normal (ULN)
Cirrhosis, recent hepatitis, alanine aminotransferase (ALT) >1.5 x ULN (i.e., above the normal range) or positive screening test for hepatitis B (hepatitis B surface antigen) or hepatitis C (by ELISA)
Uncontrolled Type 2 diabetes defined as hemoglobin A1c (HbA1c) > 9%
Heart failure defined by New York Heart Association Class III or IV
Coronary Artery Bypass Surgery (CABG) within 4 months of randomization
Use of zileuton, montelukast, coumadin or steroids
Acetaminophen use in any form in the 7 days before enrollment at Visit 1
Patients who have initiated or increased their statin dose within 8 weeks of planned randomization date
Allergy to contrast agents
Planned additional cardiac intervention (e.g., PCI, CABG) within next 6 months
Current atrial fibrillation, atrial flutter or frequent premature ventricular contractions